{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T03:42:49Z","timestamp":1792813369542,"version":"4.5.0"},"reference-count":68,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2020,3,18]],"date-time":"2020-03-18T00:00:00Z","timestamp":1584489600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,3,18]],"date-time":"2020-03-18T00:00:00Z","timestamp":1584489600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100001804","name":"Canada Research Chairs","doi-asserted-by":"publisher","award":["000"],"award-info":[{"award-number":["000"]}],"id":[{"id":"10.13039\/501100001804","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["FDN 154294"],"award-info":[{"award-number":["FDN 154294"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["FRN 132557"],"award-info":[{"award-number":["FRN 132557"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010524","name":"Campbell Family Mental Health Research Institute","doi-asserted-by":"publisher","award":["000"],"award-info":[{"award-number":["000"]}],"id":[{"id":"10.13039\/100010524","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010523","name":"Centre for Addiction and Mental Health","doi-asserted-by":"crossref","award":["000"],"award-info":[{"award-number":["000"]}],"id":[{"id":"10.13039\/100010523","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Neurobiol"],"published-print":{"date-parts":[[2020,6]]},"DOI":"10.1007\/s12035-020-01896-4","type":"journal-article","created":{"date-parts":[[2020,3,18]],"date-time":"2020-03-18T14:09:37Z","timestamp":1584540577000},"page":"2509-2520","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Human CYP2D6 Is Functional in Brain In Vivo: Evidence from Humanized CYP2D6 Transgenic Mice"],"prefix":"10.1007","volume":"57","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2655-1815","authenticated-orcid":false,"given":"Cole","family":"Tolledo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1878-5315","authenticated-orcid":false,"given":"Marlaina R.","family":"Stocco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7642-3745","authenticated-orcid":false,"given":"Sharon","family":"Miksys","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7990-2140","authenticated-orcid":false,"given":"Frank J.","family":"Gonzalez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1297-2053","authenticated-orcid":false,"given":"Rachel F.","family":"Tyndale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,3,18]]},"reference":[{"issue":"2013","key":"1896_CR1","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.pharmthera.2012.12.007","volume":"138","author":"UM Zanger","year":"2013","unstructured":"Zanger UM, Schwab M (2013)) Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation. Pharmacol Ther 138(2013):103\u2013141","journal-title":"Pharmacol Ther"},{"issue":"1","key":"1896_CR2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3109\/10408449209145319","volume":"22","author":"SA Wrighton","year":"1992","unstructured":"Wrighton SA, Stevens JC (1992) The human hepatic cytochromes P450 involved in drug metabolism. Crit Rev Toxicol 22(1):1\u201321","journal-title":"Crit Rev Toxicol"},{"issue":"1","key":"1896_CR3","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1146\/annurev.pharmtox.43.100901.140251","volume":"43","author":"X Ding","year":"2003","unstructured":"Ding X, Kaminsky LS (2003) Human extrahepatic cytochromes P450: function in xenobiotic metabolism and tissue-selective chemical toxicity in the respiratory and gastrointestinal tracts. Annu Rev Pharmacol Toxicol 43(1):149\u2013173","journal-title":"Annu Rev Pharmacol Toxicol"},{"issue":"8","key":"1896_CR4","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1056\/NEJM199308193290808","volume":"329","author":"R Michels","year":"1993","unstructured":"Michels R, Marzuk PM (1993) Medical Progress - Progress in psychiatry (1). N Engl J Med 329(8):552\u2013560","journal-title":"N Engl J Med"},{"issue":"3","key":"1896_CR5","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1124\/dmd.31.3.282","volume":"31","author":"RJ Edwards","year":"2003","unstructured":"Edwards RJ, Price RJ, Watts PS, Renwick AB, Tredger JM, Boobis AR, Lake BG (2003) Induction of cytochrome P450 enzymes in cultured precision-cut human liver slices. Drug Metab Dispos 31(3):282\u2013288","journal-title":"Drug Metab Dispos"},{"issue":"3","key":"1896_CR6","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1503\/jpn.120133","volume":"38","author":"S Miksys","year":"2013","unstructured":"Miksys S, Tyndale RF (2013) Cytochrome P450-mediated drug metabolism in the brain. J Psychiatry Neurosci 38(3):152\u2013163","journal-title":"J Psychiatry Neurosci"},{"issue":"1","key":"1896_CR7","first-page":"54","volume":"33","author":"J Yue","year":"2008","unstructured":"Yue J, Miksys S, Hoffmann E, Tyndale RF (2008) Chronic nicotine treatment induces rat CYP2D in the brain but not in the liver: an investigation of induction and time course. J Psychiatry Neurosci 33(1):54\u201363","journal-title":"J Psychiatry Neurosci"},{"issue":"7","key":"1896_CR8","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/j.neuropharm.2008.07.017","volume":"55","author":"A Mann","year":"2008","unstructured":"Mann A, Miksys S, Lee A, Mash DC, Tyndale RF (2008) Induction of the drug metabolizing enzyme CYP2D in monkey brain by chronic nicotine treatment. Neuropharmacology 55(7):1147\u20131155","journal-title":"Neuropharmacology"},{"issue":"5","key":"1896_CR9","doi-asserted-by":"crossref","first-page":"534","DOI":"10.3109\/09540261.2013.825581","volume":"25","author":"A Gaedigk","year":"2013","unstructured":"Gaedigk A (2013) Complexities of CYP2D6 gene analysis and interpretation. Int Rev Psychiatry 25(5):534\u2013553","journal-title":"Int Rev Psychiatry"},{"issue":"7","key":"1896_CR10","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.2217\/pgs.09.75","volume":"10","author":"EM Pe\u00f1as-Lled\u00f3","year":"2009","unstructured":"Pe\u00f1as-Lled\u00f3 EM, Dorado P, Pacheco R, Gonz\u00e1lez I, Llerena A (2009) Relation between CYP2D6 genotype, personality, neurocognition and overall psychopathology in healthy volunteers. Pharmacogenomics 10(7):1111\u20131120","journal-title":"Pharmacogenomics"},{"issue":"4","key":"1896_CR11","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1097\/01.jcp.0000229484.52955.22","volume":"26","author":"J Kirchheiner","year":"2006","unstructured":"Kirchheiner J, Lang U, Stamm T, Sander T, Gallinat J (2006) Association of CYP2D6 genotypes and personality traits in healthy individuals. J Clin Psychopharmacol 26(4):440\u2013442","journal-title":"J Clin Psychopharmacol"},{"issue":"1","key":"1896_CR12","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1002\/ajmg.b.20163","volume":"127","author":"RL Roberts","year":"2004","unstructured":"Roberts RL, Luty SE, Mulder RT, Joyce PR, Kennedy MA (2004) Association between cytochrome P450 2D6 genotype and harm avoidance. Am J Med Genet B Neuropsychiatr Genet 127(1):90\u201393","journal-title":"Am J Med Genet B Neuropsychiatr Genet"},{"key":"1896_CR13","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1038\/mp.2010.42","volume":"16","author":"J Kirchheiner","year":"2011","unstructured":"Kirchheiner J, Seeringer A, Godoy AL, Ohmle B, Maier C, Beschoner P, Sim EJ, Viviani R (2011) CYP2D6 in the brain: genotype effects on resting brain perfusion. Mol Psychiatry 16:333\u2013341","journal-title":"Mol Psychiatry"},{"issue":"3","key":"1896_CR14","doi-asserted-by":"crossref","first-page":"2818","DOI":"10.1016\/j.neuroimage.2011.07.052","volume":"59","author":"JC Stingl","year":"2012","unstructured":"Stingl JC, Esslinger C, Tost H, Bilek E, Kirsch P, Ohmle B, Viviani R, Walter H et al (2012) Genetic variation in CYP2D6 impacts neural activation during cognitive tasks in humans. Neuroimage 59(3):2818\u20132823","journal-title":"Neuroimage"},{"issue":"3","key":"1896_CR15","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1006\/bbrc.1998.9232","volume":"249","author":"T Hiroi","year":"1998","unstructured":"Hiroi T, Imaoka S, Funae Y (1998) Dopamine formation from tyramine by CYP2D6. Biochem Biophys Res Commun 249(3):838\u2013843","journal-title":"Biochem Biophys Res Commun"},{"issue":"3","key":"1896_CR16","first-page":"173","volume":"13","author":"AM Yu","year":"2003","unstructured":"Yu AM, Idle JR, Byrd LG, Krausz KW, K\u00fcpfer A, Gonzalez FJ (2003) Regeneration of serotonin from 5-methoxytryptamine by polymorphic human CYP2D6. Pharmacogenet Genomics 13(3):173\u2013181","journal-title":"Pharmacogenet Genomics"},{"issue":"9","key":"1896_CR17","doi-asserted-by":"crossref","first-page":"3901","DOI":"10.1210\/endo.142.9.8363","volume":"142","author":"T Hiroi","year":"2001","unstructured":"Hiroi T, Kishimoto W, Chow T, Imaoka S, Igarashi T, Funae Y (2001) Progesterone oxidation by cytochrome P450 2D isoforms in the brain. Endocrinology 142(9):3901\u20133908","journal-title":"Endocrinology"},{"issue":"2","key":"1896_CR18","first-page":"685","volume":"277","author":"T Coleman","year":"1996","unstructured":"Coleman T, Ellis SW, Martin IJ, Lennard MS, Tucker GT (1996) 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) is N-demethylated by cytochromes P450 2D6, 1A2 and 3A4 - implications for susceptibility to Parkinson's disease. J Pharmacol Exp Ther 277(2):685\u2013690","journal-title":"J Pharmacol Exp Ther"},{"issue":"4587","key":"1896_CR19","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1126\/science.6823561","volume":"219","author":"JW Langston","year":"1983","unstructured":"Langston JW, Ballard P, Tetrud JW, Irwin I (1983) Chronic parkinsonism in humans due to a product of meperidine-analog synthesis. Science 219(4587):979\u2013980","journal-title":"Science"},{"issue":"2","key":"1896_CR20","doi-asserted-by":"crossref","first-page":"144","DOI":"10.2165\/00003088-199426020-00007","volume":"26","author":"DR Krishna","year":"1994","unstructured":"Krishna DR, Klotz U (1994) Extrahepatic metabolism of drugs in humans. Clin Pharmacokinet 26(2):144\u2013160","journal-title":"Clin Pharmacokinet"},{"key":"1896_CR21","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.pnpbp.2017.04.030","volume":"78","author":"S Miksys","year":"2017","unstructured":"Miksys S, Wadji FB, Tolledo EC, Remington G, Nobrega JN, Tyndale RF (2017) Rat brain CYP2D enzymatic metabolism alters acute and chronic haloperidol side-effects by different mechanisms. Prog Neuro-Psychopharmacol Biol Psychiatry 78:140\u2013148","journal-title":"Prog Neuro-Psychopharmacol Biol Psychiatry"},{"issue":"7","key":"1896_CR22","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1038\/npp.2015.32","volume":"40","author":"DM McMillan","year":"2015","unstructured":"McMillan DM, Tyndale RF (2015) Nicotine increases codeine analgesia through the induction of brain CYP2D and central activation of codeine to morphine. Neuropsychopharmacology 40(7):1804\u20131812","journal-title":"Neuropsychopharmacology"},{"issue":"2","key":"1896_CR23","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1111\/adb.12590","volume":"24","author":"DM McMillan","year":"2019","unstructured":"McMillan DM, Miksys S, Tyndale RF (2019) Rat brain CYP2D activity alters in vivo central oxycodone metabolism, levels and resulting analgesia. Addict Biol 24(2):228\u2013238","journal-title":"Addict Biol"},{"issue":"1","key":"1896_CR24","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1111\/j.1365-2125.1994.tb04315.x","volume":"38","author":"K Rowland","year":"1994","unstructured":"Rowland K, Yeo WW, Ellis SW, Chadwick IG, Haq I, Lennard MS, Jackson PR, Ramsay LE et al (1994) Inhibition of CYP2D6 activity by treatment with propranolol and the role of 4-hydroxy propranolol. Br J Clin Pharmacol 38(1):9\u201314","journal-title":"Br J Clin Pharmacol"},{"issue":"3","key":"1896_CR25","first-page":"575","volume":"218","author":"DW Schneck","year":"1981","unstructured":"Schneck DW, Pritchard JF (1981) The inhibitory effect of propranolol pretreatment on its own metabolism in the rat. J Pharmacol Exp Ther 218(3):575\u2013581","journal-title":"J Pharmacol Exp Ther"},{"issue":"3","key":"1896_CR26","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1111\/bph.14884","volume":"177","author":"Edgor Cole Tolledo","year":"2020","unstructured":"Tolledo EC, Miksys S, Gonzales FJ, Tyndale RF (2019) Propranolol is a mechanism-based inhibitor of CYP2D and CYP2D6 in humanized CYP2D6-transgenic mice: effects on activity and drug response. Br J Pharmacol. https:\/\/doi.org\/10.1111\/bph.14884","journal-title":"British Journal of Pharmacology"},{"issue":"6","key":"1896_CR27","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1111\/j.1365-2125.1984.tb02403.x","volume":"17","author":"MS Lennard","year":"1984","unstructured":"Lennard MS, Jackson PR, Freestone S, Tucker GT, Ramsay LE, Woods HF (1984) The relationship between debrisoquine oxidation phenotype and the pharmacokinetics and pharmacodynamics of propranolol. Br J Clin Pharmacol 17(6):679\u2013685","journal-title":"Br J Clin Pharmacol"},{"issue":"6","key":"1896_CR28","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/0006-2952(91)90189-C","volume":"41","author":"Y Masubuchi","year":"1991","unstructured":"Masubuchi Y, Fujita S, Chiba M, Kagimoto N, Umeda S, Suzuki T (1991) Impairment of debrisoquine 4-hydroxylase and related monooxygenase activities in the rat following treatment with propranolol. Biochem Pharmacol 41(6):861\u2013865","journal-title":"Biochem Pharmacol"},{"key":"1896_CR29","unstructured":"McDonald AG, Tipton KF (2011) Enzymes: irreversible inhibition. eLS:1\u201317"},{"issue":"2","key":"1896_CR30","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1007\/BF02246184","volume":"120","author":"DC Hoffman","year":"1995","unstructured":"Hoffman DC, Donovan H (1995) Catalepsy as a rodent model for detecting antipsychotic drugs with extrapyramidal side effect liability. Psychopharmacology 120(2):128\u2013133","journal-title":"Psychopharmacology"},{"issue":"11","key":"1896_CR31","doi-asserted-by":"crossref","first-page":"973","DOI":"10.3109\/00498254.2013.791410","volume":"43","author":"J Cheng","year":"2013","unstructured":"Cheng J, Zhen Y, Miksys S, Beyoglu D, Krausz KW, Tyndale RF, Yu A, Idle JR et al (2013) Potential role of CYP2D6 in the central nervous system. Xenobiotica 43(11):973\u2013984","journal-title":"Xenobiotica"},{"issue":"6","key":"1896_CR32","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1038\/clpt.1985.235","volume":"38","author":"B Schmid","year":"1985","unstructured":"Schmid B, Schmid B, Bircher J, Bircher J, Preisig R, Preisig R, K\u00fcpfer A, Kupfer A (1985) Polymorphic dextromethorphan metabolism: co-segregation of oxidative O-demethylation with debrisoquin hydroxylation. Clin Pharmacol Ther 38(6):618\u2013624","journal-title":"Clin Pharmacol Ther"},{"issue":"8","key":"1896_CR33","first-page":"924","volume":"27","author":"RF Tyndale","year":"1999","unstructured":"Tyndale RF, Li Y, Li N-Y, Messina E, Miksys S, Sellers EM (1999) Characterization of cytochrome P-450 2D1 activity in rat brain: high-affinity kinetics for dextromethorphan. Drug Metab Dispos 27(8):924\u2013930","journal-title":"Drug Metab Dispos"},{"issue":"3","key":"1896_CR34","first-page":"401","volume":"184","author":"ECK Siu","year":"2006","unstructured":"Siu ECK, Wildenauer DB, Tyndale RF (2006) Nicotine self-administration in mice is associated with rates of nicotine inactivation by CYP2A5. Psychopharmacology 184(3):401\u2013408","journal-title":"Psychopharmacology"},{"issue":"6","key":"1896_CR35","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1046\/j.1471-4159.2002.01069.x","volume":"82","author":"S Miksys","year":"2002","unstructured":"Miksys S, Rao Y, Hoffmann E, Mash DC, Tyndale RF (2002) Regional and cellular expression of CYP2D6 in human brain: higher levels in alcoholics. J Neurochem 82(6):1376\u20131387","journal-title":"J Neurochem"},{"issue":"6","key":"1896_CR36","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1159\/000138140","volume":"31","author":"G Zetler","year":"1985","unstructured":"Zetler G, Baumann GH (1985) Pharmacokinetics and effects of haloperidol in the isolated mouse. Pharmacology 31(6):318\u2013327","journal-title":"Pharmacology"},{"issue":"2","key":"1896_CR37","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1007\/s00213-012-2706-0","volume":"223","author":"ID Ionov","year":"2012","unstructured":"Ionov ID, Severtsev NN (2012) Histamine-and haloperidol-induced catalepsy in aged mice: differential responsiveness to L-DOPA. Psychopharmacology 223(2):191\u2013197","journal-title":"Psychopharmacology"},{"issue":"6","key":"1896_CR38","first-page":"564","volume":"76","author":"BS Nishchal","year":"2014","unstructured":"Nishchal BS, Rai S, Prabhu MN, Ullal SD, Rajeswari S, Gopalakrishna HN (2014) Effect of Tribulus terrestris on haloperidol-induced catalepsy in mice. Indian J Pharm Sci 76(6):564\u2013567","journal-title":"Indian J Pharm Sci"},{"issue":"9","key":"1896_CR39","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1093\/pch\/16.9.535","volume":"16","author":"S Ito","year":"2011","unstructured":"Ito S (2011) Pharmacokinetics 101. Paediatr Child Health 16(9):535\u2013536","journal-title":"Paediatr Child Health"},{"issue":"1","key":"1896_CR40","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/0014-2999(76)90358-7","volume":"40","author":"A Levy","year":"1976","unstructured":"Levy A, Ngai S, Finck A, Kawashima K, Spector S (1976) Disposition of propranolol isomers in mice. Eur J Pharmacol 40(1):93\u2013100","journal-title":"Eur J Pharmacol"},{"issue":"6","key":"1896_CR41","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1124\/dmd.105.004077","volume":"33","author":"K Venkatakrishnan","year":"2005","unstructured":"Venkatakrishnan K, Obach RS (2005) In vitro-in vivo extrapolation of CYP2D6 inactivation by paroxetine: prediction of nonstationary pharmacokinetics and drug interaction magnitude. Drug Metab Dispos 33(6):845\u2013852","journal-title":"Drug Metab Dispos"},{"issue":"5","key":"1896_CR42","doi-asserted-by":"crossref","first-page":"384","DOI":"10.2174\/138920008784746382","volume":"9","author":"J Yang","year":"2008","unstructured":"Yang J, Liao M, Shou M, Jamei M, Yeo KR, Tucker GT, Rostami-Hodjegan A (2008) Cytochrome p450 turnover: regulation of synthesis and degradation, methods for determining rates, and implications for the prediction of drug interactions. Curr Drug Metab 9(5):384\u2013394","journal-title":"Curr Drug Metab"},{"issue":"1","key":"1896_CR43","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/s00210-003-0832-2","volume":"369","author":"UM Zanger","year":"2004","unstructured":"Zanger UM, Raimundo S, Eichelbaum M (2004) Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry. Naunyn Schmiedeberg's Arch Pharmacol 369(1):23\u201337","journal-title":"Naunyn Schmiedeberg's Arch Pharmacol"},{"issue":"2","key":"1896_CR44","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1093\/toxsci\/kfr240","volume":"124","author":"HJ Renaud","year":"2011","unstructured":"Renaud HJ, Cui JY, Khan M, Klaassen CD (2011) Tissue distribution and gender-divergent expression of 78 cytochrome P450 mRNAs in mice. Toxicol Sci 124(2):261\u2013277","journal-title":"Toxicol Sci"},{"issue":"2","key":"1896_CR45","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1006\/abbi.2000.1978","volume":"381","author":"N Blume","year":"2000","unstructured":"Blume N, Leonard J, Xu ZJ, Watanabe O, Remotti H, Fishman J (2000) Characterization of Cyp2d22, a novel cytochrome P450 expressed in mouse mammary cells. Arch Biochem Biophys 381(2):191\u2013204","journal-title":"Arch Biochem Biophys"},{"issue":"1","key":"1896_CR46","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/S0003-9861(03)00174-7","volume":"414","author":"D Choudhary","year":"2003","unstructured":"Choudhary D, Jansson I, Schenkman JB, Sarfarazi M, Stoilov I (2003) Comparative expression profiling of 40 mouse cytochrome P450 genes in embryonic and adult tissues. Arch Biochem Biophys 414(1):91\u2013100","journal-title":"Arch Biochem Biophys"},{"issue":"5","key":"1896_CR47","doi-asserted-by":"crossref","first-page":"195","DOI":"10.2131\/fts.4.195","volume":"4","author":"S Yamaori","year":"2017","unstructured":"Yamaori S, Jiang R, Maeda C, Ogawa R, Okazaki H, Aramaki H, Watanabe K (2017) Expression levels of 39 Cyp mRNAs in the mouse brain and neuroblastoma cell lines, C-1300N18 and NB2a\u2013strong expression of Cyp1b1. Fund Toxicol Sci 4(5):195\u2013200","journal-title":"Fund Toxicol Sci"},{"issue":"10","key":"1896_CR48","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1124\/dmd.105.005488","volume":"33","author":"S Miksys","year":"2005","unstructured":"Miksys S, Cheung C, Gonzalez FJ, Tyndale RF (2005) Human CYP2D6 and mouse CYP2Ds: organ distribution in a humanized mouse model. Drug Metab Dispos 33(10):1495\u20131502","journal-title":"Drug Metab Dispos"},{"issue":"3","key":"1896_CR49","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1097\/00008571-200104000-00007","volume":"11","author":"I Siegle","year":"2001","unstructured":"Siegle I, Fritz P, Eckhardt K, Zanger UM, Eichelbaum M (2001) Cellular localization and regional distribution of CYP2D6 mRNA and protein expression in human brain. Pharmacogenet Genomics 11(3):237\u2013245","journal-title":"Pharmacogenet Genomics"},{"issue":"2","key":"1896_CR50","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1006\/bbrc.1993.2309","volume":"196","author":"M Komori","year":"1993","unstructured":"Komori M (1993) A novel P450 expressed at the high level in rat brain. Biochem Biophys Res Commun 196(2):721\u2013728","journal-title":"Biochem Biophys Res Commun"},{"issue":"3","key":"1896_CR51","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/S0304-4165(97)00157-8","volume":"1380","author":"T Hiroi","year":"1998","unstructured":"Hiroi T, Imaoka S, Chow T, Funae Y (1998) Tissue distributions of CYP2D1, 2D2, 2D3 and 2D4 mRNA in rats detected by RT-PCR. Biochim Biophys Acta 1380(3):305\u2013312","journal-title":"Biochim Biophys Acta"},{"issue":"9","key":"1896_CR52","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1124\/dmd.30.9.970","volume":"30","author":"T Hiroi","year":"2002","unstructured":"Hiroi T, Chow T, Imaoka S, Funae Y (2002) Catalytic specificity of CYP2D isoforms in rat and human. Drug Metab Dispos 30(9):970\u2013976","journal-title":"Drug Metab Dispos"},{"issue":"7","key":"1896_CR53","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1124\/dmd.108.021261","volume":"36","author":"LA McLaughlin","year":"2008","unstructured":"McLaughlin LA, Dickmann LJ, Wolf CR, Henderson CJ (2008) Functional expression and comparative characterization of nine murine cytochromes P450 by fluorescent inhibition screening. Drug Metab Dispos 36(7):1322\u20131331","journal-title":"Drug Metab Dispos"},{"issue":"7","key":"1896_CR54","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1124\/dmd.105.008870","volume":"34","author":"AM Yu","year":"2006","unstructured":"Yu AM, Haining RL (2006) Expression, purification, and characterization of mouse Cyp2d22. Drug Metab Dispos 34(7):1167\u20131174","journal-title":"Drug Metab Dispos"},{"issue":"9","key":"1896_CR55","doi-asserted-by":"crossref","first-page":"2160","DOI":"10.1016\/j.neurobiolaging.2011.08.014","volume":"33","author":"A Mann","year":"2012","unstructured":"Mann A, Miksys SL, Gaedigk A, Kish SJ, Mash DC, Tyndale RF (2012) The neuroprotective enzyme CYP2D6 increases in the brain with age and is lower in Parkinson\u2019s disease patients. Neurobiol Aging 33(9):2160\u20132171","journal-title":"Neurobiol Aging"},{"issue":"2","key":"1896_CR56","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1081\/DMR-120034149","volume":"36","author":"S Miksys","year":"2004","unstructured":"Miksys S, Tyndale RF (2004) The unique regulation of brain cytochrome P450 2 (CYP2) family enzymes by drugs and genetics. Drug Metab Rev 36(2):313\u2013333","journal-title":"Drug Metab Rev"},{"issue":"12","key":"1896_CR57","doi-asserted-by":"crossref","first-page":"3077","DOI":"10.1111\/bph.12652","volume":"171","author":"RT Miller","year":"2014","unstructured":"Miller RT, Miksys S, Hoffmann E, Tyndale RF (2014) Ethanol self-administration and nicotine treatment increase brain levels of CYP2D in African green monkeys. Br J Pharmacol 171(12):3077\u20133088","journal-title":"Br J Pharmacol"},{"key":"1896_CR58","doi-asserted-by":"crossref","DOI":"10.1201\/b19643","volume-title":"Cytochrome P450 2D6: structure, function, regulation and polymorphism","author":"S Zhou","year":"2016","unstructured":"Zhou S (2016) Cytochrome P450 2D6: structure, function, regulation and polymorphism. CRC Press, Boca Raton, Florida"},{"issue":"1","key":"1896_CR59","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/S0022-510X(97)00179-2","volume":"153","author":"SJ McCann","year":"1997","unstructured":"McCann SJ, Pond SM, James KM, Le Couteur DG (1997) The association between polymorphisms in the cytochrome P-450 2D6 gene and Parkinson's disease: a case-control study and meta-analysis. J Neurol Sci 153(1):50\u201353","journal-title":"J Neurol Sci"},{"issue":"12","key":"1896_CR60","volume":"8","author":"Y Lu","year":"2013","unstructured":"Lu Y, Mo C, Zeng Z, Chen S, Xie Y, Peng Q, He Y, Deng Y et al (2013) CYP2D6* 4 allele polymorphism increases the risk of Parkinson\u2019s disease: evidence from meta-analysis. PLoS One 8(12):e84413","journal-title":"PLoS One"},{"key":"1896_CR61","unstructured":"Anwarullah, Aslam M, Badshah M, Abbasi R, Sultan A, Khan K, Ahmad N, von Engelhardt J, (2017). . , 18. (2017) Further evidence for the association of CYP2D6* 4 gene polymorphism with Parkinson\u2019s disease: a case control study. Genes Environ 39 (1): 18"},{"key":"1896_CR62","volume-title":"The MPTP model of Parkinson's disease","author":"S Przedborski","year":"2007","unstructured":"Przedborski S (2007) The MPTP model of Parkinson's disease. Informa Healthcare USA, Inc., New York"},{"issue":"9","key":"1896_CR63","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1002\/mds.20117","volume":"19","author":"G Alves","year":"2004","unstructured":"Alves G, Kurz M, Lie SA, Larsen JP (2004) Cigarette smoking in Parkinson's disease: influence on disease progression. Mov Disord 19(9):1087\u20131092","journal-title":"Mov Disord"},{"issue":"6","key":"1896_CR64","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1038\/sj.tpj.6500439","volume":"7","author":"A Llerena","year":"2007","unstructured":"Llerena A, Dorado P, Pe\u00f1as-Lled\u00f3 EM, C\u00e1ceres MC, De la Rubia A (2007) Low frequency of CYP2D6 poor metabolizers among schizophrenia patients. Pharmacogenomics J 7(6):408\u2013410","journal-title":"Pharmacogenomics J"},{"issue":"2","key":"1896_CR65","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1038\/tpj.2010.78","volume":"12","author":"EM Pe\u00f1as-Lled\u00f3","year":"2012","unstructured":"Pe\u00f1as-Lled\u00f3 EM, Dorado P, Ag\u00fcera Z, Gratac\u00f3s M, Estivill X, Fern\u00e1ndez-Aranda F, Llerena A (2012) CYP2D6 polymorphism in patients with eating disorders. Pharmacogenomics J 12(2):173\u2013175","journal-title":"Pharmacogenomics J"},{"issue":"4","key":"1896_CR66","doi-asserted-by":"crossref","first-page":"288","DOI":"10.2174\/187569212803901729","volume":"10","author":"EM Pe\u00f1as-Lled\u00f3","year":"2012","unstructured":"Pe\u00f1as-Lled\u00f3 EM, Gonzalez I, Dorado P, Perez B, Calzadilla LR, Alvarez M, Eugania G, Naranjo M et al (2012) Eating disorder symptoms and CYP2D6 variation in Cuban healthy females: a report from the Ibero-American network of pharmacogenetics. Current Pharmacogenomics and Personalized Medicine 10(4):288\u2013292","journal-title":"Current Pharmacogenomics and Personalized Medicine"},{"issue":"3","key":"1896_CR67","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1038\/clpt.2009.216","volume":"88","author":"AL Zackrisson","year":"2010","unstructured":"Zackrisson AL, Lindblom B, Ahlner J (2010) High frequency of occurrence of CYP2D6 gene duplication\/multiduplication indicating ultrarapid metabolism among suicide cases. Clinical Pharmacology & Therapeutics 88(3):354\u2013359","journal-title":"Clinical Pharmacology & Therapeutics"},{"issue":"2","key":"1896_CR68","doi-asserted-by":"crossref","first-page":"179","DOI":"10.2217\/pgs.11.146","volume":"13","author":"EM Pe\u00f1as-Lled\u00f3","year":"2012","unstructured":"Pe\u00f1as-Lled\u00f3 EM, Blasco-Fontecilla H, Dorado P, Vaquero-Lorenzo C, Baca-Garc\u00eda E, Llerena A (2012) CYP2D6 and the severity of suicide attempts. Pharmacogenomics 13(2):179\u2013184","journal-title":"Pharmacogenomics"}],"container-title":["Molecular Neurobiology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12035-020-01896-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12035-020-01896-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12035-020-01896-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,18]],"date-time":"2021-03-18T00:37:15Z","timestamp":1616027835000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12035-020-01896-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,18]]},"references-count":68,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020,6]]}},"alternative-id":["1896"],"URL":"https:\/\/doi.org\/10.1007\/s12035-020-01896-4","relation":{},"ISSN":["0893-7648","1559-1182"],"issn-type":[{"value":"0893-7648","type":"print"},{"value":"1559-1182","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,3,18]]},"assertion":[{"value":"22 November 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 March 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 March 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"R.F.T. has consulted for Quinn Emanuel and Ethismos. All other authors declare no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"All applicable international, national, and\/or institutional guidelines for the care and use of animals were followed. Experiments were performed in accordance with the NIH guidelines for the care and use of laboratory animals, and with approval of the University of Toronto Animal Care Committee.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}]}}